Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.

[1]  S. Gabriel,et al.  Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.

[2]  P. Kantoff,et al.  Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Boorjian,et al.  Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Bochner,et al.  Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions , 2014, Advances in urology.

[5]  K. Offit,et al.  Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  P. O’Donnell.  Bladder cancer pharmacogenomics: recent insights and future perspectives. , 2012, Pharmacogenomics.

[7]  M. Ratain,et al.  Germline pharmacogenomics in oncology: Decoding the patient for targeting therapy , 2012, Molecular oncology.

[8]  E. Gamazon,et al.  Genome-wide Meta-analysis Identifies Variants Associated with Platinating Agent Susceptibility Across Populations , 2011, The Pharmacogenomics Journal.

[9]  Brooke L. Fridley,et al.  Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients , 2011, Clinical Cancer Research.

[10]  E. Gamazon,et al.  Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. , 2011, Translational research : the journal of laboratory and clinical medicine.

[11]  Yi Shi,et al.  Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis , 2011, Medical oncology.

[12]  Y. Lotan,et al.  Contemporary use of perioperative cisplatin‐based chemotherapy in patients with muscle‐invasive bladder cancer , 2011, Cancer.

[13]  E. Gamazon,et al.  Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants , 2010, Pharmacogenetics and genomics.

[14]  Jae K. Lee,et al.  Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. , 2009, Cancer research.

[15]  S. Marsh.  Pharmacogenomics of Taxane/Platinum Therapy in Ovarian Cancer , 2009, International Journal of Gynecologic Cancer.

[16]  P. Russo,et al.  A role for neoadjuvant gemcitabine plus cisplatin in muscle‐invasive urothelial carcinoma of the bladder , 2008, Cancer.

[17]  P. Gregersen,et al.  Accounting for ancestry: population substructure and genome-wide association studies. , 2008, Human molecular genetics.

[18]  Shiwei Duan,et al.  Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. , 2007, American journal of human genetics.

[19]  Jae K. Lee,et al.  A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery , 2007, Proceedings of the National Academy of Sciences.

[20]  P. Carroll,et al.  Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. , 2007, The Journal of urology.

[21]  M. Eileen Dolan,et al.  A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity , 2007, Proceedings of the National Academy of Sciences.

[22]  Yusuke Nakamura,et al.  Validation study of the prediction system for clinical response of M‐VAC neoadjuvant chemotherapy , 2007, Cancer science.

[23]  J. Baselga,et al.  Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Yusuke Nakamura,et al.  Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  Gudmundur A. Thorisson,et al.  The International HapMap Project Web site. , 2005, Genome research.

[26]  M. Filipovic,et al.  Genotyping the Butyrylcholinesterase in Patients with Prolonged Neuromuscular Block after Succinylcholine , 2005, Anesthesiology.

[27]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[28]  Joseph L. Gastwirth,et al.  Trend Tests for Case-Control Studies of Genetic Markers: Power, Sample Size and Robustness , 2002, Human Heredity.

[29]  A. Kibel.  International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial , 2011 .